Again, IMO, I disagree. I am inclined to believe that a BP partnership would come shortly after data and that partner would not necessarily give a huge upfront payment, but would pay the bills to get LymPro through the FDA approval process over the next year or so leading up to a specific reimbursement code for LymPro so that Medicare could then cover. That partner would obviously want to see final data before any deal was done.